Neutrophil-to-lymphocyte ratio and lymphocyte count reflect alterations in central neurodegeneration-associated proteins and clinical severity in Parkinson Disease patients.

Alpha-synuclein Amyloid-beta Blood cell count Cerebrospinal fluid Lymphocytes count Neutrophil-to-lymphocyte ratio Parkinson Disease

Journal

Parkinsonism & related disorders
ISSN: 1873-5126
Titre abrégé: Parkinsonism Relat Disord
Pays: England
ID NLM: 9513583

Informations de publication

Date de publication:
Jul 2023
Historique:
received: 14 03 2023
revised: 29 05 2023
accepted: 31 05 2023
medline: 3 7 2023
pubmed: 9 6 2023
entrez: 8 6 2023
Statut: ppublish

Résumé

Peripheral inflammation has been recently associated to Parkinson disease (PD). However, how the peripheral inflammatory immune response could affect the clinical-pathological features of the disease is not fully understood. In this study, we assessed the peripheral immune profile of a well-characterized PD cohort, examining several correlations with CSF biomarkers of neurodegeneration and the main clinical parameters, aimed at better elucidating the complex dynamics of the brain-periphery interactions in PD. The leukocyte populations counts (neutrophils, lymphocytes, monocytes, eosinophils, and basophils) and the neutrophil-to-lymphocyte ratio (NLR) were collected and compared in 61 PD patients and 60 sex/age matched controls (CTRLs). Immune parameters were correlated with CSF levels of total α-synuclein, amyloid-β-42, total and phosphorylated-tau and main motor and non-motor scores. PD patients had lower lymphocyte and higher NLR counts compared to CTRLs. In PD patients, the lymphocyte count directly correlated with CSF α-synuclein levels, whereas NLR displayed an inverse correlation with the CSF amyloid-β42 levels. The lymphocyte count also negatively correlated with HY stage, while NLR positively with the disease duration. This study provided in vivo evidence that, in PD, changes in leukocytes in the periphery, assessed as relative lymphopenia and NLR increase, reflect in central neurodegeneration-associated proteins modifications, especially in α-synuclein and amyloid-β pathways, and greater clinical burden.

Identifiants

pubmed: 37290213
pii: S1353-8020(23)00203-1
doi: 10.1016/j.parkreldis.2023.105480
pii:
doi:

Substances chimiques

alpha-Synuclein 0
tau Proteins 0
Biomarkers 0
Amyloid beta-Peptides 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

105480

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest None.

Auteurs

Piergiorgio Grillo (P)

Unit of Neurology, Department of Systems Medicine, University of Roma Tor Vergata, Rome, Italy; Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.

Giulia Maria Sancesario (GM)

Clinical Neurochemistry Laboratory, IRCCS Fondazione Santa Lucia, Rome, Italy.

Roberta Bovenzi (R)

Unit of Neurology, Department of Systems Medicine, University of Roma Tor Vergata, Rome, Italy.

Henri Zenuni (H)

Unit of Neurology, Department of Systems Medicine, University of Roma Tor Vergata, Rome, Italy.

Jacopo Bissacco (J)

Unit of Neurology, Department of Systems Medicine, University of Roma Tor Vergata, Rome, Italy.

Davide Mascioli (D)

Unit of Neurology, Department of Systems Medicine, University of Roma Tor Vergata, Rome, Italy.

Clara Simonetta (C)

Unit of Neurology, Department of Systems Medicine, University of Roma Tor Vergata, Rome, Italy.

Paolo Forti (P)

Unit of Neurology, Department of Systems Medicine, University of Roma Tor Vergata, Rome, Italy.

Giulia Rebecca Degoli (GR)

Unit of Neurology, Department of Systems Medicine, University of Roma Tor Vergata, Rome, Italy.

Massimo Pieri (M)

Department of Experimental Medicine, University of Roma Tor Vergata, Rome, Italy.

Valerio Chiurchiù (V)

Institute of Translational Pharmacology, National Research Council, Rome, Italy; Laboratory of Resolution of Neuroinflammation, IRCCS Santa Lucia Foundation, Rome, Italy.

Alessandro Stefani (A)

Unit of Neurology, Department of Systems Medicine, University of Roma Tor Vergata, Rome, Italy.

Nicola Biagio Mercuri (NB)

Unit of Neurology, Department of Systems Medicine, University of Roma Tor Vergata, Rome, Italy; Experimental Neurology Unit, IRCCS Fondazione Santa Lucia, Rome, Italy.

Tommaso Schirinzi (T)

Unit of Neurology, Department of Systems Medicine, University of Roma Tor Vergata, Rome, Italy. Electronic address: t.schirinzi@yahoo.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH